Carcinoma, Bronchogenic  >>  Conmana (icotinib)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Conmana (icotinib) / Betta Pharma
NCT01465243: Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Completed
4
32
RoW
Icotinib, BPI-2009, Conmana
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
10/13
02/14
NCT01720901: Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Suspended
4
20
RoW
Icotinib, Conmana, BPI-2009
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
12/15
12/16

Download Options